about
Purine nucleoside analog--sulfinosine modulates diverse mechanisms of cancer progression in multi-drug resistant cancer cell linesElucidation and in planta reconstitution of the parthenolide biosynthetic pathway.Discovery of 14-3-3 protein-protein interaction inhibitors that sensitize multidrug-resistant cancer cells to doxorubicin and the Akt inhibitor GSK690693.Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles.New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer.Ferrocene-cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxel.Simple avarone mimetics as selective agents against multidrug resistant cancer cells.Structural differences in diarylheptanoids analogues from Alnus viridis and Alnus glutinosa influence their activity and selectivity towards cancer cells.Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivatives.Chemo-protective and regenerative effects of diarylheptanoids from the bark of black alder (Alnus glutinosa) in human normal keratinocytes.Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.Anti-cancer effects of cerium oxide nanoparticles and its intracellular redox activity.Antioxidative activity of diarylheptanoids from the bark of black alder (Alnus glutinosa) and their interaction with anticancer drugs.Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.Jatrophane diterpenoids from the latex of Euphorbia dendroides and their anti-P-glycoprotein activity in human multi-drug resistant cancer cell lines.The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines.Isolation and biological evaluation of jatrophane diterpenoids from Euphorbia dendroides.Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil.Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R).Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R).The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro.Targeting autophagy to modulate cell survival: a comparative analysis in cancer, normal and embryonic cells.Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.Genomic instability and p53 alterations in patients with malignant glioma.Transfer of Drug Resistance Characteristics Between Cancer Cell Subpopulations: A Study Using Simple Mathematical Models.DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.Anticancer properties of the abietane diterpene 6,7-dehydroroyleanone obtained by optimized extraction.Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.Two structurally distinct chalcone dimers from Helichrysum zivojinii and their activities in cancer cell lines.Diarylheptanoids from the bark of black alder inhibit the growth of sensitive and multi-drug resistant non-small cell lung carcinoma cells.Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients.Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment.Association of Overexpressed Gene with Altered and Genes Contributes to Non-small Cell Lung Carcinoma PathogenesisModulation of Antioxidant Potential with Coenzyme Q10 Suppressed Invasion of Temozolomide-Resistant Rat Glioma andInterplay of Darwinian Selection, Lamarckian Induction and Microvesicle Transfer on Drug Resistance in CancerA New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-]Pyrimidine Dual Src/P-Glycoprotein InhibitorCytotoxic Activity of Royleanone Diterpenes from BenthAntioxidant-Inspired Drug Discovery: Antitumor Metabolite Is Formed in Situ from a Hydroxycinnamic Acid Derivative upon Free-Radical Scavenging
P50
Q28484976-0B1ABF58-3D8F-4CF1-92F6-EA94EAE1BD3FQ35139943-30803050-E455-4A47-BB22-2B8BDB976A9FQ35143276-DBF5D964-8016-4FEA-8D28-93FFD9E32F2AQ37708100-348C475D-DFCC-40A4-9D12-D5ADE9B2A1B7Q38597583-22B9C942-4925-40B7-9202-3E4CE3ADF901Q38665011-03317CC9-0E9E-405D-A3D9-819D8EE97C49Q38774560-AA4774A0-E271-430B-B0D1-B0E649A7F06BQ38788846-A3D2A4F9-008F-49BC-8ADB-166954E9EAEAQ38850653-C2307A9A-CB64-4640-9ABE-58061D539BD7Q38854490-B22DD2AF-CAF5-41A0-9943-36F9238B7714Q38869271-1965A651-A544-4B47-AEA8-D91D54F64404Q38894490-A9E96045-1BFB-4CAB-B4B8-09B696D19682Q38964619-5D957132-D021-48C8-8B69-601AA049E653Q38975988-EB9DEA61-E18B-4B17-8860-2C5D32B566C9Q39256716-7776379E-0D6C-483F-9BBB-863B62974DA0Q39503691-300E04A5-27AF-45FB-BED3-A472782F6A99Q39517506-96C58D9A-4198-47FC-AAED-1DD4CE39676BQ39837066-6B3D57C2-10C3-42CE-BE3B-CFDA2C309801Q39980204-BD6129EA-A79F-48C1-9F5B-3FFEEB1682EEQ39991624-336A8365-855F-4605-A99B-DAFDB14E25A9Q40335896-8185FA2B-CC5C-4508-972A-6304102EBDEBQ41912427-F83BAA32-F175-452B-8D9F-59D1F6A59C11Q48363650-DAE94BFE-D463-48F3-9BFF-7CC0C50B0B0AQ48484152-F0E69127-14D2-4AD1-8779-1F243B393B1DQ50622208-6A1ED08E-B585-40C5-A59D-6B53B2544407Q50876153-F4FD9C6D-F69A-4D28-81F7-3724D68871C1Q52837987-8C6D91D5-D25A-44F9-AD6D-A1557489CF58Q53474990-6C0AD628-4085-4E63-8E93-4344A65812DFQ53684056-AEE89ED4-CC06-463B-9409-BC3DB77F21F6Q54107698-8691C9C9-2E1D-44A8-9D68-BB6D635CFF16Q54388909-9773F65B-AD4E-4EFC-8E78-819645202079Q54513213-8309050E-963F-40F1-8AE1-FA329DABF8BCQ54623612-403C85A2-FE8A-4453-9C8E-E9A9B2DC48C3Q54976871-035908A6-E128-48BE-A40A-30435E7D720FQ64071333-495E9051-C212-46F7-BD0B-5F6B7EA71400Q64104859-200F0AE3-69C4-4971-A88D-498113E30919Q67228081-0D36A2E4-F38E-4998-B30A-A9CD9C255315Q67228086-247CE94D-6EFA-4EEF-98C5-ABAD37F89918Q67228091-308997D0-0CF7-4A49-A0C2-A47677A24769Q67228096-2D53BE11-BD75-4259-8665-DCF2C5D85B86
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Milica Pesic
@ast
Milica Pesic
@en
Milica Pesic
@es
Milica Pesic
@nl
Milica Pesic
@sl
type
label
Milica Pesic
@ast
Milica Pesic
@en
Milica Pesic
@es
Milica Pesic
@nl
Milica Pesic
@sl
altLabel
Milica Pešić
@en
Vesna Pesic
@en
prefLabel
Milica Pesic
@ast
Milica Pesic
@en
Milica Pesic
@es
Milica Pesic
@nl
Milica Pesic
@sl
P106
P1153
36768679400
P1960
BjU5f-0AAAAJ
P21
P31
P496
0000-0002-9045-8239